Glaxo dips a lonely big pharma toe into the coeliac space
With the buyout of Sitari Pharmaceuticals, Glaxosmithkline becomes only the second major drug maker to have an interest in coeliac disease.
Stryker spends $500m to re-up on robots
Deal is the fifth largest robotics surgery purchase ever, and the second big move from Stryker.
Vertex spends nearly $1bn on Semma's unproven diabetes cell tech
Having succeeded with cystic fibrosis Vertex is now chasing a cure for type 1 diabetes.
Zogenix gets an unwelcome distraction from Fintepla
Spending $250m on Modis gives Zogenix a new rare disease niche, but the timing and the target both look odd.
Atricure lassoes Sentreheart for $40m
Ablation company takes on a new tech, and responsibility for an expensive clinical trial.
$1bn Corindus deal gets Healthineers off the acquisition blocks
Vascular robotics is growing fast and Corindus is the leader here, but Healthineers will need an aggressive sales plan.
Bluerock unlikely to smooth Bayer’s rocky road
Bayer has responded to its current woes by going all in on cell therapy – a move that, even if successful, will take a long time to pay off.
A recap on the past few months of data digging and analysis
Using EvaluatePharma data Vantage explored investment trends in biopharma and medtech, sales per employee at big drug makers, and the declining number of late-stage…
Abbvie hopes to turn around the fortunes of Sting
Continued interest in the Sting pathway might come as a surprise, though secrecy suggests that asset prices are failing.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.